Lactin-V significantly reduces recurrence of bacterial vaginosis


  • Heather Mason
  • Univadis Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

The use of Lactin-V after treatment with vaginal metronidazole significantly reduces the recurrence incidence of bacterial vaginosis, according to a study in the New England Journal of Medicine.

The randomised, double-blind, placebo-controlled Phase IIb trial recruited women who had received a diagnosis of bacterial vaginosis and a five-day course of 0.75% metronidazole gel, within 30 days of screening. Women between the ages of 18 and 45 years, received vaginally administered Lactobacillus crispatus CTV-05 (Lactin-V)(N=152) or placebo (N=76) for 11 weeks and followed up for 24 weeks.

The primary outcome, recurrence of bacterial vaginosis by week 12, occurred in 46 participants (30%) in the treatment group and 34 participants (45%) in the placebo group, risk ratio 0.66 (95% CI 0.44-0.87; P=.01) and 0.73 (95% CI 0.54-0.92) at 24 weeks.

In the treatment group, L. crispatus CTV-05 was detected in 79 to 84 per cent at weeks 4, 8 and 12, and 48 per cent of participants at week 24. In the placebo group, L. crispatus CTV-05 was detected in 2-6 per cent of participants at weeks 4, 8 and 12, and in 2 per cent of participants at week 24.

Treatment-related adverse events did not differ between groups.